CRISPR in Drug Discovery – ELRIG virtual event

Home/External conference, Virtual Conference/CRISPR in Drug Discovery – ELRIG virtual event
Loading Events
This event has passed.

Metrion’s Sales and Marketing Manager Dr Sophie Rose and Business Development Executive Anca Haralambie will be attending the third CRISPR in Drug Discovery: From Targets to Therapeutics meeting hosted by ELRIG, to be held on 23rd and 24th March 2021 as a virtual event.

The event will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and the pioneering applications in therapeutic genome editing.

If you would like to arrange a 1:1 meeting with either Sophie or Anca at the event please email

Metrion Biosciences is a UK-based Contract Research Organization (CRO) located within the Cambridge bio cluster, one of Europe’s largest bioscience research hubs. Our state of the art laboratories at Granta Park house high quality facilities for native and engineered cell line and induced pluripotent stem cell culture, a comprehensive suite of automated patch clamp platforms, multiple manual patch clamp rigs, fluorescence-based screening capability and laboratory data management and reporting systems. Our company is focused upon delivering a range of high quality ion channel drug discovery services. We provide highly skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays. We combine in depth target class knowledge and high quality screening assays with highly experienced and collaborative drug discovery managers to keep your research focused upon meeting both objectives and timelines. Our team has successfully delivered many projects on behalf of our clients from once off screening projects to fully integrated drug discovery programmes delivering clinical candidates.

Go to Top